|Journal||Journal of Allergy and Clinical Immunology: In Practice|
|State||Published - 1 Nov 2020|
Access to Document
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, No. 10, 01.11.2020, p. 3622-3625.e19.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures
AU - Glickman, Jacob W.
AU - Han, Joseph
AU - Garcet, Sandra
AU - Krueger, James G.
AU - Pavel, Ana B.
AU - Guttman-Yassky, Emma
N1 - Funding Information: Conflicts of interest: J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, MedImmune/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB; and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2020/11/1
Y1 - 2020/11/1
UR - http://www.scopus.com/inward/record.url?scp=85089375421&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.07.015
DO - 10.1016/j.jaip.2020.07.015
M3 - Article
C2 - 32702518
AN - SCOPUS:85089375421
SN - 2213-2198
VL - 8
SP - 3622-3625.e19
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 10